162 related articles for article (PubMed ID: 1869342)
1. Pharmacokinetics of oral cefatrizine in patients with impaired renal function.
Couet W; Fauvel JP; Laville M; Pozet N; Fourtillan JB
Int J Clin Pharmacol Ther Toxicol; 1991 Jun; 29(6):213-7. PubMed ID: 1869342
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of oral cefatrizine in pregnant and non-pregnant women with reference to fetal distribution.
Papantoniou N; Ismailos G; Daskalakis G; Karabinas C; Mesogitis S; Papapanagiotou A; Antsaklis A
Fetal Diagn Ther; 2007; 22(2):100-6. PubMed ID: 17135753
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacokinetics of cefatrizine administered in repeated doses].
Couet W; Reigner BG; Lefebvre MA; Bizouard J; Fourtillan JB
Pathol Biol (Paris); 1988 May; 36(5):513-6. PubMed ID: 3043350
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
Ikeda M; Furukawa H; Imamura H; Shimizu J; Ishida H; Masutani S; Tatsuta M; Kawasaki T; Satomi T
Cancer Chemother Pharmacol; 2002 Jul; 50(1):25-32. PubMed ID: 12111108
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of cicletanine in patients with impaired renal function.
Jungers P
Drugs Exp Clin Res; 1988; 14(2-3):189-94. PubMed ID: 3416723
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of buflomedil after intravenous administration in patients with chronic renal failure.
Rey E; d'Athis P; Richard MO; Fillastre JP; Olive G
Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):648-52. PubMed ID: 6526539
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of ofloxacin in healthy subjects and patients with varying degrees of renal impairment.
Flor S; Guay D; Opsahl J; Tack K; Matzke G
Int J Clin Pharmacol Res; 1991; 11(3):115-21. PubMed ID: 1809697
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of cefatrizine after oral administration in human volunteers.
Mastrandrea V; Ripa S; La Rosa F; Ghezzi A
Int J Clin Pharmacol Res; 1985; 5(5):319-23. PubMed ID: 4066082
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
[TBL] [Abstract][Full Text] [Related]
10. A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
O'Donnell A; Punt CJ; Judson I; Van Maanen L; Suttle AB; Ertel P; Beale P
Cancer Chemother Pharmacol; 2003 Jan; 51(1):58-66. PubMed ID: 12497207
[TBL] [Abstract][Full Text] [Related]
11. Disposition kinetics of dibekacin in normal subjects and in patients with renal failure.
Arancibia A; Chávez J; Ibarra R; Ruiz I; Icarte A; Thambo S; Chávez H
Int J Clin Pharmacol Ther Toxicol; 1987 Jan; 25(1):38-43. PubMed ID: 3557728
[TBL] [Abstract][Full Text] [Related]
12. Effects of renal function on recainam pharmacokinetics and pharmacodynamics.
Cheng JW; Charland SL; Goldfarb S; Spinler SA
Clin Pharmacol Ther; 1995 May; 57(5):492-8. PubMed ID: 7768071
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of anakinra in subjects with different levels of renal function.
Yang BB; Baughman S; Sullivan JT
Clin Pharmacol Ther; 2003 Jul; 74(1):85-94. PubMed ID: 12844139
[TBL] [Abstract][Full Text] [Related]
14. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
Perucca E; Cloyd J; Critchley D; Fuseau E
Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
[TBL] [Abstract][Full Text] [Related]
16. Increased potency and decreased elimination of lamifiban, a GPIIb-IIIa antagonist, in patients with severe renal dysfunction.
Lehne G; Nordal KP; Midtvedt K; Goggin T; Brosstad F
Thromb Haemost; 1998 Jun; 79(6):1119-25. PubMed ID: 9657435
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function.
Arancibia A; Drouguett MT; Fuentes G; González G; González C; Thambo S; Palombo G
Int J Clin Pharmacol Ther Toxicol; 1982 Oct; 20(10):447-53. PubMed ID: 7141752
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to patients with chronic renal failure and healthy control subjects.
Danielson B; Querin S; LaRochelle P; Sultan E; Mouren M; Bryce T; Stepniewski JP; Lenfant B
J Cardiovasc Pharmacol; 1994; 23 Suppl 4():S50-9. PubMed ID: 7527102
[TBL] [Abstract][Full Text] [Related]
19. Comparison of zopiclone pharmacokinetics in patients with impaired renal function and normal subjects. Effect of hemodialysis.
Marc-Aurele J; Caille G; Bourgoin J
Sleep; 1987; 10 Suppl 1():22-6. PubMed ID: 3438644
[TBL] [Abstract][Full Text] [Related]
20. No need to adjust the dose of 311C90 (zolmitriptan), a novel anti-migraine treatment, in patients with renal failure not requiring dialysis.
Gillotin C; Bagnis C; Mamet JP; Peck RW; Deray G
Int J Clin Pharmacol Ther; 1997 Nov; 35(11):522-6. PubMed ID: 9401835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
